SUNJIN BEAUTY SCIENCE CO. LTD.

SUNJIN BEAUTY SCIENCE CO. LTD.

KKRX:086710
6,340.00
KRW
-120.00
(-1.86%)
516.56EPS
15.90P/E
79.39BMarket Cap
Nov 12Next Earn
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
5,234.96
4,827.75
2,026.46
5,308.47
6,041.98
6,604.54
6,720.24
6,904.9
Basic EPS, GAAP
450
273.5
49.5
1,620
467
759
496
415.6
Free Cash Flow per Basic Share
-2,163.11
95.08
-557.05
-527.4
-862.68
-1,074.42
-744.38
-542.56
Dividend per Share
33.72
15.01
19.65
29.04
46.44
94.73
166.63
106.74
Book Value per Share
2,983.32
3,219.86
3,816.05
5,375.73
5,816.83
6,569.02
7,045.31
7,180.01
Tangible Book Value per Share
2,899.39
3,140.19
3,759.01
5,320.15
5,764.57
6,518.8
6,928.33
7,074.64
Basic Weighted Avg Shares
9
10
24
12
12
12
12
12
Sales/Revenue/Turnover
47,403
46,392
48,703
64,332
72,622
79,372
80,766
82,935
Operating Margin (%)
9.82
7.67
7.6
8.27
12.45
13.41
7.5
4.2
Depreciation Expense
2,934
3,992
4,304
4,788
5,438
6,057
7,374
8,177
Net Income, GAAP
4,075
2,628
1,190
19,632
5,613
9,122
5,961
4,992
Effective Tax Rate (%)
3.33
- -
- -
18.54
7.05
6.21
- -
- -
Profit Margin (%)
8.6
5.67
2.44
30.52
7.73
11.49
7.38
6.02
Working Capital
7,969
8,506
22,782
24,212
12,915
6,054
12,788
13,483
LT Debt
30,090
33,668
40,688
33,916
23,625
28,302
44,437
39,768
Total Equity
30,180
32,804
48,578
66,867
72,836
82,819
89,024
90,829
Return on Invested Capital (%)
- -
- -
- -
3.94
7.14
7.86
- -
- -
Return on Capital (%)
- -
- -
- -
18.77
5.37
7.49
- -
- -
Return on Common Equity (%)
- -
8.81
3.07
35.37
8.35
12.26
7.29
5.9

Capital Structure

KRW

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
23,922
28,830
32,329
LT Borrowings
44,330
42,910
39,691
LT Finance Leases
107
88
77
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
12
12
12
Market Capitalization
112,296
115,058
79,388

Working Capital

KRW

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
50,673
57,551
60,246
Cash, Cash Equivalents & STI
12,586
12,040
12,925
Accounts Receivable, Net
9,560
- -
14,440
Inventories
26,547
28,192
29,984
Total Current Liabilities
37,885
46,993
46,764
Payables & Accruals
- -
- -
- -
ST Debt
23,922
28,830
32,329
Deferred Revenue
- -
- -
- -

Growth Rates

KRW

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
23.17%
7.49%
Free Cash Flow
- -
-312.31%
-30.71%
Net Income, GAAP
- -
290.39%
-34.65%
Sales/Revenue/Turnover
- -
12.2%
1.76%
Total Cash Common Dividend
- -
88.09%
75.91%

Quarterly Revenue

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
20,794
21,843
18,229
18,507
79,372
2025
22,488
21,648
18,856
17,774
80,766
2026
22,733
23,572
- -
- -
- -

Quarterly Earnings Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
271
183
92
213.29
759
2025
235
156
67.3
38.5
496
2026
150.78
159
- -
- -
- -

Quarterly Dividends Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
57.2
37.54
-33.05
33.04
94.73
2025
- -
- -
106.75
- -
166.63
2026
- -
- -
- -
- -
- -

Company Description

CEO
Seong-Ho Lee
Full Time Employees
228
Sector
Process industries
Industry
Industrial specialties
Address
Seoul South Korea
IPO Date
Jan 27, 2021
Business
Sunjin Beauty Science Co., Ltd. is a South Korea-based specialty chemicals company primarily engaged in the research, development, manufacture, and distribution of cosmetic raw materials, active cosmetic ingredients, and finished personal care formulations. The company operates across several core product categories and service divisions: Inorganic and Organic UV Filters, producing surface-treated zinc oxide, micronized titanium dioxide, liquid UV dispersions, and encapsulated sun protection compounds marketed under brand lines including SUNZnO, SUNTiO, and SUNSIL-TinNatural; Microbeads and Sensory Modifiers, supplying porous and non-porous silica beads under the SUNSIL series, poly-methyl methacrylate (PMMA) micro-powders under the SUNPMMA brand, and biodegradable natural cellulose powders engineered as sustainable alternatives to microplastics for texture enhancement and optical blurring; Color Cosmetic Ingredients, providing surface-treated pigments, specialized binders, and pigment dispersions for foundations, cushions, and makeup applications; Emulsifiers and Rheology Modifiers, offering water-in-oil (W/O) emulsification systems, polymeric stabilizers, and naturally derived functional surfactants; Turnkey ODM/OEM Formulation Services, developing and manufacturing finished functional skincare, makeup, and over-the-counter (OTC) sunscreen formulations; Proprietary Consumer Brands, marketing finished clean-beauty skincare products through its in-house brand i-RECIPE; and Clinical Efficacy Testing Services, conducted through its Sunjin Clinical Research Center (SCRC) to provide in vitro and in vivo safety, efficacy, and SPF rating verification. The company serves global cosmetic conglomerates, contract manufacturers, and indie beauty brands across Asia, Europe, North America, and South America, supplying key materials to major industry clients including L'Oréal, Estée Lauder, and Amorepacific. Founded in 1978 as Sunjin Chemical Co., Ltd., the company rebranded to Sunjin Beauty Science Co., Ltd. in 2016 and completed its initial public offering on the KOSDAQ exchange in 2021 under ticker 086710. The company is headquartered in Seoul, South Korea, and operates state-of-the-art synthesis, extraction, and cleanroom manufacturing facilities at its cGMP- and US FDA-compliant Janghang industrial complex in Seocheon-gun, Chungcheongnam-do, supported by international business entities and operational subsidiaries in the United States, China, Italy, and Indonesia. In recent strategic and operational developments, Sunjin Beauty Science has vertically expanded its business model from raw ingredient supply into full-service finished cosmetic and OTC sunscreen ODM/OEM manufacturing, completing a 25.4 billion KRW dedicated OTC production facility at its Janghang complex designed to meet stringent U.S. Modernization of Cosmetics Regulation Act (MoCRA) standards and European safety frameworks. Concurrently, the company has scaled up production capacity for high-margin natural silica and sustainable sensory beads to capture surging demand driven by global regulatory bans on synthetic microplastics, broadened the testing scope of its Sunjin Clinical Research Center to offer integrated global compliance validation, and strengthened its direct overseas commercial presence through the establishment of dedicated local sales and distribution entities in the United States and Southeast Asia.